193 related articles for article (PubMed ID: 22198693)
1. Optic neuritis after infliximab therapy.
Faillace C; de Almeida JR; de Carvalho JF
Rheumatol Int; 2013 Apr; 33(4):1101-3. PubMed ID: 22198693
[TBL] [Abstract][Full Text] [Related]
2. [Optic neuritis associated with infliximab].
Tran TH; Milea D; Cassoux N; Bodaghi B; Bourgeois P; LeHoang P
J Fr Ophtalmol; 2005 Feb; 28(2):201-4. PubMed ID: 15851955
[TBL] [Abstract][Full Text] [Related]
3. [Retrobulbar optic neuritis associated with Infliximab].
Bidaguren A; Müller-Thyssen A; Blanco A; Mendicute J; Ubeda M
Arch Soc Esp Oftalmol; 2007 Feb; 82(2):109-12. PubMed ID: 17323251
[TBL] [Abstract][Full Text] [Related]
4. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Hochman D; Wolff B
JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
[No Abstract] [Full Text] [Related]
5. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Callegari PE; Schaible TF; Boscia JA
JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
[No Abstract] [Full Text] [Related]
6. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Costenbader KH; Glass R; Cui J; Shadick N
JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
[No Abstract] [Full Text] [Related]
7. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Okada SK; Siegel JN
JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
[No Abstract] [Full Text] [Related]
8. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.
Simsek I; Erdem H; Pay S; Sobaci G; Dinc A
Ann Rheum Dis; 2007 Sep; 66(9):1255-8. PubMed ID: 17456525
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
[TBL] [Abstract][Full Text] [Related]
10. Optic neuritis in a psoriatic arthritis patient treated by infliximab.
Minami-Hori M; Tsuji H; Takahashi H; Hanada K; Iizuka H
J Dermatol; 2013 Apr; 40(4):298-9. PubMed ID: 23289758
[No Abstract] [Full Text] [Related]
11. Infliximab-associated retrobulbar optic neuritis.
Mejico LJ
Arch Ophthalmol; 2004 May; 122(5):793-4. PubMed ID: 15136342
[No Abstract] [Full Text] [Related]
12. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab-associated multiple sclerosis.
Bensouda-Grimaldi L; Mulleman D; Valat JP; Autret-Leca E
J Rheumatol; 2007 Jan; 34(1):239-40; discussion 240. PubMed ID: 17216704
[No Abstract] [Full Text] [Related]
14. Drugs for rheumatoid arthritis.
Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
[No Abstract] [Full Text] [Related]
15. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
16. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
17. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
[No Abstract] [Full Text] [Related]
18. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
19. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.
Flendrie M; Creemers MC; Welsing PM; den Broeder AA; van Riel PL
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii30-3. PubMed ID: 14532145
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF agents for rheumatoid arthritis.
Seymour HE; Worsley A; Smith JM; Thomas SH
Br J Clin Pharmacol; 2001 Mar; 51(3):201-8. PubMed ID: 11298065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
